General Information of the Protein
Protein ID
PT01080
Protein Name
Dual specificity mitogen-activated protein kinase kinase 1
Secondarily
Protein Name
ERK activator kinase 1
MAPK/ERK kinase 1
Gene Name
MAP2K1
Secondarily
Gene Name
MEK1
PRKMK1
Sequence
MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
STE protein kinase group
>
STE protein kinase STE7 family
Function
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
    Show/Hide
Uniprot ID
Q02750
Ensembl ID
ENSG00000169032
HGNC ID
HGNC:6840
Subcellular Location
Cytoplasm
Cytoskeleton
Microtubule organizing center
Centrosome
Cytoplasm
Cytoskeleton
Microtubule organizing center
Spindle pole body
Cytoplasm
Nucleus
Membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000045 , A-375
Compound ID Compound Name Compound Formula
CP0061810
4-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1H-indazole-5-carboxamide
   Show/Hide
C16H14FIN4O3
 1
1
EC50 = 0.4 nM
   TI
   LI
   LO
   TS
CP0116131
7-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,2-benzothiazole-6-carboxamide
   Show/Hide
C16H13FIN3O3S
 1
1
EC50 = 0.9 nM
   TI
   LI
   LO
   TS
CP0301325
N-[(2R)-2,3-dihydroxypropoxy]-7-(2-fluoro-4-iodoanilino)-1,2-benzothiazole-6-carboxamide
   Show/Hide
C17H15FIN3O4S
 1
1
EC50 = 1.1 nM
   TI
   LI
   LO
   TS
CP0270741
N-(cyclopropylmethoxy)-4-(2-fluoro-4-iodoanilino)-1H-indazole-5-carboxamide
   Show/Hide
C18H16FIN4O2
 1
1
EC50 = 1.5 nM
   TI
   LI
   LO
   TS
CP0061813
N-ethoxy-4-(2-fluoro-4-iodoanilino)-1H-indazole-5-carboxamide
   Show/Hide
C16H14FIN4O2
 1
1
EC50 = 2.4 nM
   TI
   LI
   LO
   TS
CP0139330
N-[(2R)-2,3-dihydroxypropoxy]-4-(2-fluoro-4-iodoanilino)-1H-indazole-5-carboxamide
   Show/Hide
C17H16FIN4O4
 1
1
EC50 = 3.7 nM
   TI
   LI
   LO
   TS
CP0339840
4-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-1H-indazole-5-carboxamide
   Show/Hide
C16H14BrFN4O3
 1
1
EC50 = 6.4 nM
   TI
   LI
   LO
   TS
CP0319000
7-fluoro-3-(2-fluoro-4-iodoanilino)-N-[(2S)-2-hydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide
   Show/Hide
C17H14F2IN3O4
 1
1
EC50 = 7.2 nM
   TI
   LI
   LO
   TS
CP0318998
N-[(2R)-2,3-dihydroxypropoxy]-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide
   Show/Hide
C17H15FIN3O5
 1
1
EC50 = 34 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0131900
N-[2-[2-[2-[2-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
   Show/Hide
C40H44F5IN10O6
 1
1 IC50 = 0.015 nM
CP0116312
2-[(2S)-2,3-dihydroxypropyl]-8-(2-fluoro-4-iodoanilino)pyrido[3,4-d]pyridazin-1-one
   Show/Hide
C16H14FIN4O3
 1
1 IC50 = 1.63 nM
CP0027641
(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
   Show/Hide
C17H15F2IN4O4
 2
1 IC50 = 1.79 nM
2 IC50 = 3.2 nM
CP0215324
3-cyanoquinoline, 8
   Show/Hide
C28H29ClN6O3S
 1
1 IC50 = 2 nM
CP0133877
6-Methoxy-7-(3-morpholin-4-yl-propoxy)-4-(4-phenoxy-phenylamino)-quinoline-3-carbonitrile
   Show/Hide
C30H30N4O4
 3
1 IC50 = 2.4 nM
2 IC50 = 4 nM
3 IC50 = 7 nM
CP0158653
Pimasertib
   Show/Hide
C15H15FIN3O3
 1
1 IC50 = 3.39 nM
CP0026322
N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
   Show/Hide
C16H14F3IN2O4
 8
1 IC50 = 5.2 nM
2 IC50 = 7 nM
3 IC50 = 13 nM
4 IC50 = 15 nM
5 IC50 = 82 nM
6 Kd = 0.4 nM
7 Kd = 31 nM
8 Kd = 44 nM
CP0382258
N-[(2S)-2,3-dihydroxypropyl]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
   Show/Hide
C14H14FIN4O3
 1
1 IC50 = 5.37 nM
CP0550678
2-[(2S)-2,3-dihydroxypropyl]-8-(2-fluoro-4-iodoanilino)-4-methylpyrido[3,4-d]pyridazin-1-one
   Show/Hide
C17H16FIN4O3
 1
1 IC50 = 11.4 nM
CP0158116
4-({3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl}-amino)-7-[(1E)-4-(4-ethylpiperazin-1-yl)but-1-enyl]quinoline-3-carbonitrile
   Show/Hide
C30H32ClN7S
 1
1 IC50 = 12 nM
CP0116131
7-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,2-benzothiazole-6-carboxamide
   Show/Hide
C16H13FIN3O3S
 2
1 IC50 = 12 nM
2 IC50 = 15 nM
CP0317919
3-[(2S)-2,3-dihydroxypropyl]-5-(2-fluoro-4-iodoanilino)pyrido[3,4-d]pyrimidin-4-one
   Show/Hide
C16H14FIN4O3
 1
1 IC50 = 12.3 nM
CP0061810
4-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1H-indazole-5-carboxamide
   Show/Hide
C16H14FIN4O3
 1
1 IC50 = 13 nM
CP0273467
2-chloro-N-[(2S)-2,3-dihydroxypropyl]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
   Show/Hide
C14H13ClFIN4O3
 1
1 IC50 = 13 nM
CP0139330
N-[(2R)-2,3-dihydroxypropoxy]-4-(2-fluoro-4-iodoanilino)-1H-indazole-5-carboxamide
   Show/Hide
C17H16FIN4O4
 1
1 IC50 = 15 nM
CP0301325
N-[(2R)-2,3-dihydroxypropoxy]-7-(2-fluoro-4-iodoanilino)-1,2-benzothiazole-6-carboxamide
   Show/Hide
C17H15FIN3O4S
 1
1 IC50 = 20 nM
CP0807912
((2S,3S)-2-{(R)-4-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]-2,5-dioxo-imidazolidin-1-yl}-N-(2-fluoro-4-iodo-phenyl)-3-phenylbutyramide
   Show/Hide
C28H27FIN3O6
 1
1 IC50 = 25 nM
CP0318998
N-[(2R)-2,3-dihydroxypropoxy]-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide
   Show/Hide
C17H15FIN3O5
 1
1 IC50 = 25 nM
CP0554907
N-[(2R)-2,3-dihydroxypropyl]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
   Show/Hide
C14H14FIN4O3
 1
1 IC50 = 30.2 nM
CP0571209
N-(1,3-dihydroxypropan-2-yl)-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
   Show/Hide
C14H14FIN4O3
 1
1 IC50 = 31.3 nM
CP0095543
3-[(2R)-2,3-dihydroxypropyl]-5-(2-fluoro-4-iodoanilino)pyrido[3,4-d]pyrimidin-4-one
   Show/Hide
C16H14FIN4O3
 1
1 IC50 = 33.6 nM
CP0319000
7-fluoro-3-(2-fluoro-4-iodoanilino)-N-[(2S)-2-hydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide
   Show/Hide
C17H14F2IN3O4
 1
1 IC50 = 35 nM
CP0113690
5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethyl)pyrimidine-4-carboxamide
   Show/Hide
C13H12FIN4O2
 1
1 IC50 = 49.6 nM
CP0273468
5-(2-fluoro-4-iodoanilino)-N-(3-hydroxypropyl)pyrimidine-4-carboxamide
   Show/Hide
C14H14FIN4O2
 1
1 IC50 = 60.1 nM
CP0270741
N-(cyclopropylmethoxy)-4-(2-fluoro-4-iodoanilino)-1H-indazole-5-carboxamide
   Show/Hide
C18H16FIN4O2
 1
1 IC50 = 79 nM
CP0061813
N-ethoxy-4-(2-fluoro-4-iodoanilino)-1H-indazole-5-carboxamide
   Show/Hide
C16H14FIN4O2
 1
1 IC50 = 93 nM
CP0339840
4-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-1H-indazole-5-carboxamide
   Show/Hide
C16H14BrFN4O3
 1
1 IC50 = 125 nM
CP0029366
US8497274, 32
   Show/Hide
C27H18F4N4O3S
 1
1 IC50 < 300 nM
Clinical Information about the Protein
Target 1 ( ERK activator kinase 1 (MEK1) )
Target Type Clinical trial Target
Disease 2 Target-related Diseases  2
1 Melanoma [ICD-11: 2C30]
2 Cardiac arrest [ICD-11: MC82]
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 Selumetinib Phase 3
Melanoma
Investigative Drug(s) 1 Investigative Drug  1
1 PD98059 Investigative
Cardiac arrest
Target 2 ( HUMAN ERK activator kinase 1 (MEK1) )
Target Type Unknown Type Target
Disease 2 Target-related Diseases  2
1 Neurofibromatosis type 1 [ICD-11: LD2D.10]
2 Metastatic melanoma [ICD-11: 2E2Z]
Investigative Drug(s) 2 Investigative Drugs  2
1 Selumetinib Approved
Neurofibromatosis type 1
2 Trametinib Approved
Metastatic melanoma